{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+ALL&page=30", "query": { "condition": "Relapsed/Refractory ALL", "page": 30 }, "page_size": 10 }, "pagination": { "page": 30, "page_size": 10, "total_count": 3664, "total_pages": 367, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+ALL&page=31&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2FRefractory+ALL&page=29&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-11T13:19:26.609Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02341014", "title": "Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "T-cell Lymphomas", "Relapsed or Refractory" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Romidepsin", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2015-01-02", "completion_date": "2023-01-11", "has_results": true, "last_update_posted_date": "2024-04-04", "last_synced_at": "2026-11-11T13:19:26.609Z", "location_count": 6, "location_summary": "Omaha, Nebraska • Basking Ridge, New Jersey • Commack, New York + 3 more", "locations": [ { "city": "Omaha", "state": "Nebraska" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02341014" }, { "nct_id": "NCT01632826", "title": "Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2019-11-12", "last_synced_at": "2026-11-11T13:19:26.609Z", "location_count": 25, "location_summary": "Duarte, California • Greenbrae, California • Los Angeles, California + 21 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "West Palm Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01632826" }, { "nct_id": "NCT00903968", "title": "Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Plerixafor", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2009-06-01", "completion_date": "2016-10", "has_results": true, "last_update_posted_date": "2020-06-02", "last_synced_at": "2026-11-11T13:19:26.609Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Hyannis, Massachusetts • Milford, Massachusetts + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Hyannis", "state": "Massachusetts" }, { "city": "Milford", "state": "Massachusetts" }, { "city": "Newton", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00903968" }, { "nct_id": "NCT01638936", "title": "BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "BT062 , intravenous administration", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biotest Pharmaceuticals Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2012-07-03", "completion_date": "2018-10-30", "has_results": false, "last_update_posted_date": "2019-07-23", "last_synced_at": "2026-11-11T13:19:26.609Z", "location_count": 10, "location_summary": "Duarte, California • Los Angeles, California • Jacksonville, Florida + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01638936" }, { "nct_id": "NCT00450944", "title": "Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Albert Einstein College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "17 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "17 Years to 120 Years" }, "enrollment_count": 10, "start_date": "2006-02-22", "completion_date": "2010-04-01", "has_results": false, "last_update_posted_date": "2021-04-14", "last_synced_at": "2026-11-11T13:19:26.609Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00450944" }, { "nct_id": "NCT03331198", "title": "Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia, Lymphocytic, Chronic, B-Cell", "Lymphoma, Small Lymphocytic" ], "interventions": [ { "name": "JCAR017 (lisocabtagene maraleucel)", "type": "BIOLOGICAL" }, { "name": "JCAR017 (lisocabtagene maraleucel) + ibrutinib", "type": "BIOLOGICAL" }, { "name": "JCAR017 (lisocabtagene maraleucel) + venetoclax", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Juno Therapeutics, a Subsidiary of Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 320, "start_date": "2017-11-27", "completion_date": "2027-11-26", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-11-11T13:19:26.609Z", "location_count": 83, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 41 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03331198" }, { "nct_id": "NCT01742793", "title": "An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hodgkin's Lymphoma", "Mature T-cell Lymphoma", "Multiple Myeloma" ], "interventions": [ { "name": "lenalidomide (Revlimid) and romidepsin (Istodax)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 12, "start_date": "2012-10", "completion_date": "2016-08", "has_results": false, "last_update_posted_date": "2020-03-04", "last_synced_at": "2026-11-11T13:19:26.609Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01742793" }, { "nct_id": "NCT03379584", "title": "A Safety Study of SGN-CD48A in Patients With Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "SGN-CD48A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2018-02-20", "completion_date": "2019-08-23", "has_results": false, "last_update_posted_date": "2019-09-18", "last_synced_at": "2026-11-11T13:19:26.609Z", "location_count": 6, "location_summary": "San Francisco, California • New Haven, Connecticut • Tampa, Florida + 3 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03379584" }, { "nct_id": "NCT07735533", "title": "A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, B Cell", "Lymphoma Non-Hodgkin", "High Grade B Cell Lymphoma", "Richter Transformation Lymphoma", "Grade 3b Follicular Lymphoma", "Primary Mediastinal B Cell Lymphoma", "Diffuse Large B Cell Lymphoma (DLBCL)" ], "interventions": [ { "name": "UB-VV400", "type": "GENETIC" }, { "name": "Rapamycin (sirolimus)", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "DRUG" ], "sponsor": "Umoja Biopharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 274, "start_date": "2026-11", "completion_date": "2031-08", "has_results": false, "last_update_posted_date": "2026-11-10", "last_synced_at": "2026-11-11T13:19:26.609Z", "location_count": 2, "location_summary": "Irvine, California • Nashville, Tennessee", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07735533" }, { "nct_id": "NCT00334438", "title": "Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "yttrium Y 90 ibritumomab tiuxetan", "type": "RADIATION" }, { "name": "Indium 111 ibritumomab tiuxetan", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 12, "start_date": "2006-07", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2016-12-23", "last_synced_at": "2026-11-11T13:19:26.609Z", "location_count": 2, "location_summary": "Hackensack, New Jersey • Chapel Hill, North Carolina", "locations": [ { "city": "Hackensack", "state": "New Jersey" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00334438" } ] }